Fludarabine
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)Small moleculePhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 89/ 100
Competitive context
61 Active assets in the Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Cyclophosphamide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Bexarotene Case Comprehensive Cancer Center | Phase 4 | BBB |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 2 | BBB |
FILGRASTIM City of Hope Medical Center | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →